Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects
NCT ID: NCT00166322
Last Updated: 2008-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2004-01-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981
Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release
NCT03223844
Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia
NCT06673966
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia
NCT03911726
Oculomotor and Spatial Cognition Deficits in Schizophrenia
NCT00931996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IBZM-SPECT (bolus and constant infusion paradigm)
single IBZM-SPECT assessment at study inclusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects at risk for the development of schizophrenia (prodromal symptoms)
* Healthy subjects
* Written informed consent
Exclusion Criteria
* Women during pregnancy or lactation
* Occupational exposition to radiation \> 15mSv
* Medication known to interfere with IBZM
* Contraindications for the use of amphetamine challenge
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ludwig-Maximilians - University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Munich
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver Pogarell, MD
Role: PRINCIPAL_INVESTIGATOR
Dept. of Psychiatry, University of Munich
Klaus Tatsch, MD
Role: PRINCIPAL_INVESTIGATOR
Dept. of Nuclear Medicine, University of Munich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of Psychiatry
Munich, , Germany
Dept. of Nuclear Medicine
Munich, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EK076/03
Identifier Type: -
Identifier Source: secondary_id
DYN-SPECT-Pogarell
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.